Raising the bar for the adjuvant treatment of pancreatic cancer
Mené au Japon sur 385 patients atteints d'un carcinome canalaire invasif du pancréas, cet essai multicentrique randomisé de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de la gemcitabine et du S-1 en chimiothérapie adjuvante
The pace of therapeutic advances in pancreatic cancer has been painstakingly slow. A stark example of this can be witnessed in patients with early stage disease, in whom rates of long-term survival have remained fairly stagnant during the past few decades. A succession of clinical trials assessing various adjuvant regimens, consisting of systemic therapy with or without radiation, have only confirmed the sobering reality that cure still very much represents the exception, rather than the rule, in individuals undergoing so-called curative resection of their pancreatic cancer.
The Lancet , commentaire, 2015